USLU, S. Et Al. 2018. THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry. Annual European Congress of Rheumatology, EULAR 2018 , (Amsterdam, Netherlands), 329.

USLU, S., CAN, G., ŞENEL, S., DALKILIÇ, H. E., İNANÇ, G. N., AKAR, S., ... KOCAER, S. B.(2018). THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry . Annual European Congress of Rheumatology, EULAR 2018 (pp.329). Amsterdam, Netherlands

USLU, SADETTİN Et Al. "THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry," Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands, 2018

USLU, SADETTİN Et Al. "THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry." Annual European Congress of Rheumatology, EULAR 2018 , Amsterdam, Netherlands, pp.329, 2018

USLU, S. Et Al. (2018) . "THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry." Annual European Congress of Rheumatology, EULAR 2018 , Amsterdam, Netherlands, p.329.

@conferencepaper{conferencepaper, author={SADETTİN USLU Et Al. }, title={THU0218 The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry}, congress name={Annual European Congress of Rheumatology, EULAR 2018}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={329} }